Do analysts rate KEQU or BEAT?

HeartBeam has a consensus target price of $4.00, indicating a potential upside of 788.69%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts plainly believe HeartBeam is more favorable than Kewaunee Scientific. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kewaunee Scientific 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 HeartBeam 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is BEAT or LUNG more profitable?

HeartBeam has a net margin of 0.00% compared to Pulmonx's net margin of -55.03%. Pulmonx's return on equity of -96.66% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% Pulmonx -55.03% -96.66% -38.32%

Is BEAT or LNSR more profitable?

LENSAR has a net margin of 57.57% compared to HeartBeam's net margin of 0.00%. LENSAR's return on equity of -529.08% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% LENSAR 57.57% -529.08% 50.03%

Is BEAT or MBOT more profitable?

Microbot Medical's return on equity of -21.87% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% Microbot Medical N/A -21.87% -20.76%

Is HYPR or BEAT more profitable?

HeartBeam has a net margin of 0.00% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -97.88% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -210.75% -97.88% -61.81% HeartBeam N/A -686.78% -348.65%

HeartBeam (BEAT) Competitors

$0.45 0.00 (-1.01%)

Closing price 09/2/2026 04:00 PM Eastern

Extended Trading

$0.45 +0.00 (+0.64%)

As of 05:03 AM Eastern

Compare

BEAT vs. KEQU, LUNG, LNSR, MBOT, and HYPR

Should you buy HeartBeam stock or one of its competitors? HeartBeam's main competitors and comparable companies include Kewaunee Scientific (KEQU), Pulmonx (LUNG), LENSAR (LNSR), Microbot Medical (MBOT), and Hyperfine (HYPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does HeartBeam compare to Kewaunee Scientific?

Kewaunee Scientific (NASDAQ:KEQU) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

HeartBeam has a consensus target price of $4.00, indicating a potential upside of 788.69%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts plainly believe HeartBeam is more favorable than Kewaunee Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kewaunee Scientific	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Kewaunee Scientific has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, HeartBeam has a beta of -0.8, meaning that its share price is 180% less volatile than the broader market.

Kewaunee Scientific has a net margin of 3.41% compared to HeartBeam's net margin of 0.00%. Kewaunee Scientific's return on equity of 14.10% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kewaunee Scientific	3.41%	14.10%	5.55%
HeartBeam	N/A	-686.78%	-348.65%

Kewaunee Scientific has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kewaunee Scientific	$282M	0.37	$9.62M	$3.22	11.28
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A

In the previous week, Kewaunee Scientific had 3 more articles in the media than HeartBeam. MarketBeat recorded 3 mentions for Kewaunee Scientific and 0 mentions for HeartBeam. Kewaunee Scientific's average media sentiment score of 1.05 beat HeartBeam's score of 0.00 indicating that Kewaunee Scientific is being referred to more favorably in the media.

Company	Overall Sentiment
Kewaunee Scientific	Positive
HeartBeam	Neutral

32.7% of Kewaunee Scientific shares are held by institutional investors. Comparatively, 7.8% of HeartBeam shares are held by institutional investors. 14.1% of Kewaunee Scientific shares are held by company insiders. Comparatively, 18.0% of HeartBeam shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Kewaunee Scientific beats HeartBeam on 11 of the 16 factors compared between the two stocks.

How does HeartBeam compare to Pulmonx?

HeartBeam (NASDAQ:BEAT) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

HeartBeam currently has a consensus price target of $4.00, suggesting a potential upside of 788.69%. Pulmonx has a consensus price target of $7.67, suggesting a potential upside of 236.26%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts plainly believe HeartBeam is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Pulmonx had 4 more articles in the media than HeartBeam. MarketBeat recorded 4 mentions for Pulmonx and 0 mentions for HeartBeam. Pulmonx's average media sentiment score of 1.10 beat HeartBeam's score of 0.00 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Overall Sentiment
HeartBeam	Neutral
Pulmonx	Positive

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 18.0% of HeartBeam shares are held by insiders. Comparatively, 7.5% of Pulmonx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

HeartBeam has a beta of -0.8, indicating that its stock price is 180% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

HeartBeam has a net margin of 0.00% compared to Pulmonx's net margin of -55.03%. Pulmonx's return on equity of -96.66% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
Pulmonx	-55.03%	-96.66%	-38.32%

HeartBeam has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
Pulmonx	$90.50M	1.08	-$54M	-$1.16	N/A

Summary

HeartBeam beats Pulmonx on 9 of the 16 factors compared between the two stocks.

How does HeartBeam compare to LENSAR?

HeartBeam (NASDAQ:BEAT) and LENSAR (NASDAQ:LNSR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

HeartBeam has higher earnings, but lower revenue than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
LENSAR	$58.44M	1.79	-$34.28M	-$0.33	N/A

LENSAR has a net margin of 57.57% compared to HeartBeam's net margin of 0.00%. LENSAR's return on equity of -529.08% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
LENSAR	57.57%	-529.08%	50.03%

In the previous week, HeartBeam's average media sentiment score of 0.00 equaled LENSAR'saverage media sentiment score.

Company	Overall Sentiment
HeartBeam	Neutral
LENSAR	Neutral

HeartBeam presently has a consensus price target of $4.00, indicating a potential upside of 788.69%. LENSAR has a consensus price target of $11.50, indicating a potential upside of 35.29%. Given HeartBeam's stronger consensus rating and higher possible upside, equities analysts clearly believe HeartBeam is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

HeartBeam has a beta of -0.8, suggesting that its stock price is 180% less volatile than the broader market. Comparatively, LENSAR has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 18.0% of HeartBeam shares are held by company insiders. Comparatively, 65.8% of LENSAR shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

LENSAR beats HeartBeam on 8 of the 14 factors compared between the two stocks.

How does HeartBeam compare to Microbot Medical?

HeartBeam (NASDAQ:BEAT) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 18.0% of HeartBeam shares are held by company insiders. Comparatively, 4.7% of Microbot Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

HeartBeam presently has a consensus target price of $4.00, indicating a potential upside of 788.69%. Microbot Medical has a consensus target price of $6.38, indicating a potential upside of 336.64%. Given HeartBeam's stronger consensus rating and higher probable upside, equities research analysts plainly believe HeartBeam is more favorable than Microbot Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Microbot Medical has higher revenue and earnings than HeartBeam. Microbot Medical is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
Microbot Medical	$346K	283.41	-$13.14M	-$0.24	N/A

HeartBeam has a beta of -0.8, meaning that its share price is 180% less volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

Microbot Medical's return on equity of -21.87% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
Microbot Medical	N/A	-21.87%	-20.76%

In the previous week, Microbot Medical had 1 more articles in the media than HeartBeam. MarketBeat recorded 1 mentions for Microbot Medical and 0 mentions for HeartBeam. Microbot Medical's average media sentiment score of 1.02 beat HeartBeam's score of 0.00 indicating that Microbot Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
HeartBeam	Neutral
Microbot Medical	Positive

Summary

Microbot Medical beats HeartBeam on 9 of the 15 factors compared between the two stocks.

How does HeartBeam compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

HeartBeam has a net margin of 0.00% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -97.88% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-210.75%	-97.88%	-61.81%
HeartBeam	N/A	-686.78%	-348.65%

In the previous week, Hyperfine had 1 more articles in the media than HeartBeam. MarketBeat recorded 1 mentions for Hyperfine and 0 mentions for HeartBeam. Hyperfine's average media sentiment score of 0.00 equaled HeartBeam'saverage media sentiment score.

Company	Overall Sentiment
Hyperfine	Neutral
HeartBeam	Neutral

HeartBeam has lower revenue, but higher earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$16.54M	5.17	-$35.57M	-$0.38	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 7.8% of HeartBeam shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by insiders. Comparatively, 18.0% of HeartBeam shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Hyperfine has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, HeartBeam has a beta of -0.8, meaning that its stock price is 180% less volatile than the broader market.

Hyperfine currently has a consensus target price of $2.03, indicating a potential upside of 152.27%. HeartBeam has a consensus target price of $4.00, indicating a potential upside of 788.69%. Given HeartBeam's stronger consensus rating and higher possible upside, analysts plainly believe HeartBeam is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Hyperfine beats HeartBeam on 8 of the 15 factors compared between the two stocks.

Get HeartBeam News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BEAT vs. The Competition

Export

Metric	HeartBeam	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.62M	$5.75B	$7.20B	$12.67B
Dividend Yield	N/A	1.76%	2.53%	8.56%
P/E Ratio	-0.88	25.86	272.66	25.23
Price / Sales	N/A	81.12	634.53	104.56
Price / Cash	N/A	33.05	76.98	52.08
Price / Book	3.00	6.08	12.97	6.10
Net Income	-$21.01M	$147.75M	$3.47B	$348.86M
7 Day Performance	-7.31%	-0.73%	-0.11%	-1.90%
1 Month Performance	-8.48%	3.79%	6.75%	1.96%
1 Year Performance	-68.08%	7.39%	25.08%	15.30%

HeartBeam Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BEAT HeartBeam	1.8075 of 5 stars	$0.45 -1.0%	$4.00 +788.7%	-69.9%	$25.62M	N/A	N/A	1,700
KEQU Kewaunee Scientific	1.3808 of 5 stars	$37.70 +0.1%	N/A	-35.2%	$108.19M	$282M	11.71	1,231	Gap Up
LUNG Pulmonx	2.714 of 5 stars	$2.49 -0.6%	$7.67 +208.5%	+31.8%	$106.73M	$90.50M	N/A	250	Positive News
LNSR LENSAR	2.2354 of 5 stars	$8.60 -3.8%	$11.50 +33.7%	-31.2%	$105.69M	$58.44M	N/A	110	Gap Down
MBOT Microbot Medical	2.3418 of 5 stars	$1.48 -1.7%	$6.38 +332.2%	-61.1%	$99.08M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BEAT) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartBeam (BEAT) Competitors

BEAT vs. KEQU, LUNG, LNSR, MBOT, and HYPR

How does HeartBeam compare to Kewaunee Scientific?

Summary

How does HeartBeam compare to Pulmonx?

Summary

How does HeartBeam compare to LENSAR?

Summary

How does HeartBeam compare to Microbot Medical?

Summary

How does HeartBeam compare to Hyperfine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAT vs. The Competition

HeartBeam Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartBeam (BEAT) Competitors

BEAT vs. KEQU, LUNG, LNSR, MBOT, and HYPR

How does HeartBeam compare to Kewaunee Scientific?

Do analysts rate KEQU or BEAT?

Which has more risk & volatility, KEQU or BEAT?

Is KEQU or BEAT more profitable?

Which has better valuation & earnings, KEQU or BEAT?

Does the media prefer KEQU or BEAT?

Do insiders & institutionals have more ownership in KEQU or BEAT?

Summary

How does HeartBeam compare to Pulmonx?

Do analysts recommend BEAT or LUNG?

Does the media favor BEAT or LUNG?

Do institutionals & insiders hold more shares of BEAT or LUNG?

Which has more risk and volatility, BEAT or LUNG?

Is BEAT or LUNG more profitable?

Which has higher earnings & valuation, BEAT or LUNG?

Summary

How does HeartBeam compare to LENSAR?

Which has stronger valuation and earnings, BEAT or LNSR?

Is BEAT or LNSR more profitable?

Does the media favor BEAT or LNSR?

Do analysts rate BEAT or LNSR?

Which has more volatility and risk, BEAT or LNSR?

Do institutionals & insiders have more ownership in BEAT or LNSR?

Summary

How does HeartBeam compare to Microbot Medical?

Do insiders and institutionals believe in BEAT or MBOT?

Do analysts prefer BEAT or MBOT?

Which has better valuation and earnings, BEAT or MBOT?

Which has more risk & volatility, BEAT or MBOT?

Is BEAT or MBOT more profitable?

Does the media prefer BEAT or MBOT?

Summary

How does HeartBeam compare to Hyperfine?

Is HYPR or BEAT more profitable?

Does the media refer more to HYPR or BEAT?

Which has stronger valuation and earnings, HYPR or BEAT?

Do institutionals and insiders have more ownership in HYPR or BEAT?

Which has more volatility & risk, HYPR or BEAT?

Do analysts rate HYPR or BEAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAT vs. The Competition

HeartBeam Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools